Research Papers:
The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1988 views | HTML 2807 views | ?
Abstract
Tsung-Ming Chang1,*, Yan-Shen Shan2,3,*, Pei-Yi Chu4,1,5,*, Shih Sheng Jiang1, Wen-Chun Hung1, Yu-Lin Chen1, Hsiu-Chi Tu1, Hui-You Lin1, Hui-Jen Tsai1,6,7 and Li-Tzong Chen1,6,7,8
1National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
2Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan
3Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan
4Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan
5School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
6Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
7Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
8Institute of Molecular Medicine, National Cheng Kung University, Tainan, Taiwan
*These authors contributed equally to this work
Correspondence to:
Hui-Jen Tsai, email: [email protected]
Keywords: pancreatic neuroendocrine tumor, PTEN, LKB1, mTOR, c-Myc
Received: June 15, 2017 Accepted: September 03, 2017 Published: September 16, 2017
ABSTRACT
Pancreatic neuroendocrine tumor (pNET) is an uncommon type of pancreatic neoplasm. Low Phosphatase and Tensin Homologue (PTEN) expression and activation of the mechanistic target of rapamycin (mTOR) pathway have been noted in pNETs, and the former is associated with poor survival in pNET patients. Based on the results of the RADIANT-3 study, everolimus, an oral mTOR inhibitor, has been approved to treat advanced pNETs. However, the exact regulatory mechanism for the mTOR pathway in pNETs remains largely unknown. PTEN and liver kinase B1 (LKB1) are well-known for their regulatory role in the mTOR pathway. We evaluated the expression of PTEN and LKB1 in 21 pNET patients, and low PTEN and LKB1 expression levels were noted in 48% and 24% of the patients, respectively. Loss of PTEN and LKB1 synergistically promoted cell proliferation of pNET, attenuated the sensitivity of cells to mTOR inhibitors and enhanced c-Myc expression, which back-regulated PTEN, AKT, mTOR and its downstream effectors. For pNET cells with low expression levels of PTEN and LKB1, silencing the expression of c-Myc by shRNA reduced their proliferative rate, while adding either c-Myc inhibitor or AMP-activated protein kinase activator reversed their resistance to mTOR inhibitors in vitro and in vivo. Furthermore, high c-Myc expression was subsequently identified in 81% of pNETs, suggesting that up-regulation of c-Myc expression in pNETs may occur through PTEN/LKB1-dependent and PTEN/LKB1-independent regulation. The results delineated the regulation of PTEN and LKB1 on the AKT/mTOR/c-Myc axis and suggested that both c-Myc and mTOR are potential therapeutic targets for pNET.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20956